High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's Disease.
Dawn R EbachTraci W JesterJoseph A GalankoAnn M FirestineRana AmmouryJose CabreraJulie BassPhillip MinarKelly OlanoPeter A MargolisKelly SandbergTiffany M LinnvilleJess KaplanLisa PitchSteven J SteinerDorsey BassJonathan MosesJeremy AdlerAjay S GulatiPrateek D WaliDinesh PashankarAnastasia IvanovaHans H HerfarthDavid Alain WohlKeith J BenkovJennifer StropleJillian SullivanJeanne TungZarela L Molle-RiosShehzad Ahmed SaeedAthos BousvarosMichael D KappelmanPublished in: The American journal of gastroenterology (2024)
Overweight and obese patients with PCD are more likely to experience ADA treatment failure than those with normal BMI. Higher BMI was associated with lower drug trough levels. Standard ADA dosing may be insufficient for overweight children with PCD. Among IFX initiators, there was no observed difference in clinical outcomes or drug levels, perhaps due to weight-based dosing and/or greater use of proactive drug monitoring.